Company
FARAN is a modern and fast-growing Greek pharmaceutical company, with a history of 70 years in the pharmaceutical market.
FARAN aims to offer recognized therapeutic proposals of high quality and value, modern pharmaceutical technology, and established safety.
FARAN achieves this goal by utilizing the extensive experience of its executives in the field of Health, by operating based on the needs and particularities of the Greek reality, and by adopting high quality in its structure and functions.
FARAN offers solutions to a wide range of diseases in the segments of Oncology, Haematology, Nephrology, Rheumatology, Endocrinology, Pathology, Gynaecology, Virology, and Cardiology (see all therapeutic areas), through selected international collaborations and armed with the trust of the medical community.
Vision, Mission, Values
Our Vision is to become one of the leading European pharmaceutical companies worldwide while having a positive impact on people’s lives and on the community, through the provision of high-quality products as well as a commitment and contribution to science.
Our Mission is for our brand to remain synonymous with quality, safety, and reliability, from the perspectives of the end-users of our products, our partners, as well as the healthcare system in which we operate.
Our Core Values include:
- empowerment through ownership and accountability
- a commitment to diversity, equity, and inclusion
- treating others with respect, humility, and empathy
- maintaining a growth mindset
History
FARAN LABORATORIES S.A was founded by Dimitrios Katsikas and quickly became one of the largest pharmaceutical companies in the Greek market, making FARAN a historical Greek Pharmaceutical Company.
FARAN’s growing success sparks the interest of Italy’s Angelini Pharma Group who initiate an acquisition of the company’s commercial operations. Marios Katsikas invested some of the capital from the acquisition to co-found PROTON PHARMA.
The newly-established entity boasted a team of established professionals with long-standing careers in multinational entities within the pharmaceutical sector. Proton quickly positioned itself as a strong contender in the branded generics market.
The company is rebranded as FARAN S.A., returning back to its roots. Faran’s vision is to become a leader in and to provide a benchmark for each therapeutic category in which it operates.
Standards
QUALITY – Faran maintains quality standards certified according to ISO 9001:2015 and also according to the Ministerial Decision for Medical Devices (Lloyd’s – UKAS). Learn More »
PHARMACOVIGILANCE – Faran has established a modern Risk Management and Pharmacovigilance system in compliance with the EU and International Directives. Learn More »
COMPLIANCE – Faran has implemented modern compliance practices in accordance with all local laws and procedures. As such, it has in place and fully observes an internal Code of Professional Practices and Policies (FP3). Learn More »
DISCLOSURE – Faran publicizes all donations, grants, and endorsements it makes to healthcare organizations and professionals according to EU laws and practices. Learn More »
Partners
Financial Data
FARAN has experienced consistent sales growth during a period when public spending on the pharmaceutical sector dropped drastically and has since stagnated – a testament to the business acumen and strategic vision of its leadership team.